A COMMUNITY EXPERIENCE OF THE NOVEL ANTICOAGULANT PRADAXA

A COMMUNITY EXPERIENCE OF THE NOVEL ANTICOAGULANT PRADAXA

Methods We retrospectively analyzed the demographics, bleeding rates, stroke rates, and any reasons for discontinuation of dabigatran in patients who were treated with dabigatran for non-valvular atrial fibrillation over the 12 month period between November 2010 (FDA approval of dabigran) through Oc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2012-03, Vol.59 (13), p.E601-E601
Hauptverfasser: Rajdev, Archana, Bradley, Jacqueline, Petrini, Joann, Alexander, Jonathan
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Cardiology
Cardiovascular
Drug therapy
FDA approval
Internal Medicine
Medical research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods We retrospectively analyzed the demographics, bleeding rates, stroke rates, and any reasons for discontinuation of dabigatran in patients who were treated with dabigatran for non-valvular atrial fibrillation over the 12 month period between November 2010 (FDA approval of dabigran) through October 2011.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(12)60602-0